Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02120469 · ClinicalTrials.gov registry record · Phase 1
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
A Phase 1 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT02120469 is a Phase 1 study that has completed, run by City of Hope Medical Center. The registered enrollment target is 27 participants.
The verdict
NCT02120469, a Phase 1 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This phase I/IB trial studies the side effects and best dose of eribulin mesylate and everolimus in treating patients with breast cancer that does not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 protein (triple-negative) and has spread to other places in the body (metastatic). Eribulin mesylate and everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- DRUG everolimus
- DRUG eribulin mesylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2014-10-01 |
| Est. Completion | 2020-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02120469
The ClinicalTrials.gov registry entry for NCT02120469 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT02120469 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02120469 about?
NCT02120469 is a clinical study titled "Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer". This phase I/IB trial studies the side effects and best dose of eribulin mesylate and everolimus in treating patients with breast cancer that does not have estrogen receptors, progesterone receptors, or large amounts of human epidermal growth factor receptor 2 protein (triple-negative) and has sprea...
What is the current status of trial NCT02120469?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2014-10-01. Estimated completion is 2020-03-03.
What interventions are being tested in trial NCT02120469?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), everolimus (DRUG), eribulin mesylate (DRUG).
Who is sponsoring clinical trial NCT02120469?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.